Nonpartisan civic infrastructure
AllCiv·Legis1
·

S. 526

BillFederalSenateIn Committee
To strengthen the use of patient-experience data within the benefit-risk framework for approval of new drugs.
About This Bill
Committee
Latest Action · February 16, 2023
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Congress
118th (2023–2025)
Introduced
February 16, 2023
Cosponsors (5)
1D 4R
View PDF ↗

Summary

Highlight any text to annotate
Better Empowerment Now to Enhance Framework and Improve Treatments Act of 2023 or the BENEFIT Act of 2023 This bill requires the Food and Drug Administration (FDA) to consider relevant patient experience data in the risk-benefit assessment framework used in the process for approving new drugs. After a new drug application has been approved, the FDA's public statement about how it used patient experience data shall include a description of how such data was considered in the risk-benefit assessment framework.

Take Action

Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.